VB 2011

Drug Profile

VB 2011

Alternative Names: H-11; H-11 scFv; Novomab-G2 scFv; VB2-011

Latest Information Update: 12 Feb 2007

Price : $50

At a glance

  • Originator Viventia Biotech
  • Developer University of Alabama at Birmingham
  • Class Antibody diagnostics; Antineoplastics; Immunoglobulin Fv fragments
  • Mechanism of Action Diagnostic imaging enhancers; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Breast cancer; Cancer; Lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 04 Oct 2000 Novopharm Biotech is now called Viventia Biotech
  • 19 Sep 2000 Preclinical development for Breast cancer in Canada (IV)
  • 01 Dec 1999 A study has been added to the adverse events and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top